Combined Inhibition of DDR1 and CDK4/6 Induces Synergistic Effects in ER-Positive, HER2-Negative Breast Cancer with PIK3CA/AKT1 Mutations

DDR1 knockdown and DDR1 pharmacological inhibitor decreased cell growth and inhibited cell cycle progression in breast cancer cell lines, while enhanced the sensitivity of PIK3CA/AKT1 mutant cells to palbociclib.